Sanofi completes acquisition of Inhibrx, Inc. to enhance rare disease pipeline
05/30/24, 1:13 PM
Location
paris
san diegoIndustry
pharmaceutical
medical
biotechnology
health care
biotechnology
biopharma
therapeutics
Sanofi has successfully completed its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 to Sanofi’s rare disease pipeline, aiming to provide better treatment options for AATD patients and strengthen Sanofi’s capabilities in the healthcare sector.
Company Info
Location
Paris, Ile De France, France
Company info
LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Holdings plc (Gyroscope), a clinical-stage gene therapy company focused on diseases of the eye, today announced that Sanofi, a global biopharmaceutical company, has committed to invest up to USD $60.0 million (GBP £44.5 million) in equity in Gyroscope.